This is a news story, published by Yahoo Finance, that relates primarily to Pfizer news.
For more Pfizer news, you can click here:
more Pfizer newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
PFE Stock. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Cheap stocks news, average PFE stock price target news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
PfizerTipRanks
•74% Informative
Pfizer ( Pfizer ) trades at just 12 times consensus 2024 earnings estimates, less than half the valuation of the broader market.
Pfizer 's 5.7% dividend yield makes it one of the top-yielding stocks in the S&P 500 right now.
The company is moving forward with the development of a once-daily oral weight-loss drug called danuglipron based on strong pharmacokinetic data.
Plus, the stock offers a 5.7% yield. Additionally, while it is still in the early innings and success is far from guaranteed, Pfizer ’s progress with its once-daily weight loss drug candidate gives the company an intriguing catalyst that could reignite interest in the stock and drive shares higher. We’ve seen what weight loss drugs have done for the shares of Pfizer ’s fellow pharma giants like Eli Lilly and Novo Nordisk , so even a bit of success in this area could be a boon for shares of Pfizer at these levels..
VR Score
68
Informative language
64
Neutral language
13
Article tone
semi-formal
Language
English
Language complexity
46
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
10
Source diversity
2
Affiliate links
no affiliate links